Needham & Company LLC reiterated their buy rating on shares of Hologic (NASDAQ:HOLX) in a research note issued to investors on Tuesday, MarketBeat reports. Needham & Company LLC currently has a $50.00 price target on the medical equipment provider’s stock, up from their previous price target of $48.00.

A number of other research firms have also weighed in on HOLX. Bank of America raised Hologic from a neutral rating to a buy rating and set a $50.00 price objective for the company in a research report on Thursday, January 4th. Piper Jaffray Companies reaffirmed a buy rating and set a $48.00 price objective on shares of Hologic in a research report on Thursday, November 9th. Evercore ISI started coverage on Hologic in a research report on Wednesday, January 3rd. They set an outperform rating and a $50.00 price objective for the company. Royal Bank of Canada reaffirmed a hold rating and set a $42.00 price objective on shares of Hologic in a research report on Friday, September 22nd. Finally, Jefferies Group reaffirmed a buy rating and set a $44.00 price objective (down previously from $49.00) on shares of Hologic in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $48.79.

Hologic (NASDAQ HOLX) traded down $0.01 on Tuesday, hitting $43.55. The stock had a trading volume of 2,975,900 shares, compared to its average volume of 2,708,563. The stock has a market cap of $12,050.00, a PE ratio of 16.50, a PEG ratio of 2.01 and a beta of 0.95. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. Hologic has a 52 week low of $35.76 and a 52 week high of $46.80.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. During the same quarter last year, the company earned $0.52 EPS. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. sell-side analysts predict that Hologic will post 2.13 EPS for the current fiscal year.

In other Hologic news, Director Elaine Ullian sold 9,282 shares of Hologic stock in a transaction on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Karleen Marie Oberton sold 1,023 shares of Hologic stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. In the last three months, insiders sold 12,099 shares of company stock valued at $487,223. Corporate insiders own 0.79% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in HOLX. Royce & Associates LP purchased a new position in shares of Hologic in the 2nd quarter worth $908,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Hologic in the 2nd quarter worth $213,000. Principal Financial Group Inc. boosted its stake in shares of Hologic by 4.5% in the 2nd quarter. Principal Financial Group Inc. now owns 452,260 shares of the medical equipment provider’s stock worth $20,524,000 after buying an additional 19,512 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Hologic by 0.4% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock worth $944,000 after buying an additional 85 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of Hologic by 21.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,892 shares of the medical equipment provider’s stock worth $540,000 after buying an additional 2,080 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

WARNING: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2018/01/12/needham-company-llc-reaffirms-buy-rating-for-hologic-holx.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.